SGM 101

Drug Profile

SGM 101

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SurgiMAb
  • Developer Centre for Human Drug Research; Institut du Cancer de Montpellier - Val d'Aurelle; Leiden University Medical Center; SurgiMAb
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Pancreatic cancer; Rectal cancer
  • Phase I Breast cancer
  • No development reported Gastric cancer

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Gastric-cancer(Diagnosis) in France (IV)
  • 13 May 2016 SurgiMab initiates enrolment in a phase I trial for Breast cancer (IV)
  • 05 Feb 2016 SurgiMab initiates enrolment in a phase I trial for Rectal cancer and Pancreatic cacner (Diagnosis) in Netherlands (IV) (EudraCT2015-003281-88)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top